September 2008 Br J Cardiol 2008;15:231-36
BJCardio editorial team
GISSI-HF shows benefit for PUFA in heart failure Two new studies from the Italian GISSI group show that n-3 polyunsaturated fatty acids (PUFA) supplementation improves morbidity and mortality in those with symptomatic heart failure, but statins don’t have any benefit in the same type of patients. The results were presented during a hotline session at the Congress and published simultaneously in The Lancet (Lancet 2008; DOI:10.1016/S0140-6736[08]61239-8, and Lancet 2008;DOI:10.1016/S0140-6736[08]61240-4). Long-term administration of PUFA reduced all-cause mortality by 9%, which the investigators say was a modest effect, and they also cut
January 2008 Br J Cardiol 2008;15:7-11
BJCardio editorial team
The ENHANCE study compared two years of treatment with ezetimibe/simvastatin 10/80 mg versus simvastatin 80 mg alone in 720 FH patients. The primary end point was the mean change in the intima-media thickness (IMT) measured at three sites in the carotid arteries. This showed no statistically significant difference between treatment groups, with the change from baseline being 0.0111 mm for the ezetimibe/simvastatin group versus 0.0058 mm for the simvastatin alone group (p=0.29). Key secondary imaging end points, cardiac events and adverse events were also not different between the two groups. Ezetimibe was, however, associated with a greater
November 2006 Br J Cardiol 2006;13:386-90
BJCardio editorial team
No content available
September 2005 Br J Cardiol 2005;12:379-86
Lena M Izzat, Philip Avery
No content available
January 2003 Br J Cardiol 2003;10:59-68
Rubin Minhas
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits